#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): September 12, 2017



STRATA SKIN SCIENCES, INC. (Exact Name of Registrant Specified in Charter)

Delaware (State or Other Jurisdiction of Incorporation)

000-51481 (Commission File Number)

13-3986004 (I.R.S. Employer Identification No.)

**19044** (Zip Code)

100 Lakeside Drive, Suite 100, Horsham, Pennsylvania (Address of Principal Executive Offices)

Registrant's telephone number, including area code: 215-619-3200

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate	e by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

#### Item 7.01 Regulation FD Disclosure

On September 15, 2017, Strata Skin Sciences (the "Company") posted an investor presentation to its website at http://investors.strataskinsciences.com/investors/home. A copy of the investor presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed subject to the requirements of amended Item 10 of Regulation S-K, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The furnishing of this information hereby shall not be deemed an admission as to the materiality of any such information.

#### Item 9.01 Financial Statements and Exhibits

(d) Exhibits

 $99.1\ Strata\ Skin\ Sciences\ Investor\ Presentation\ dated\ September\ 12,\ 2017.$ 

#### SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

#### STRATA SKIN SCIENCES, INC.

Date: September 15, 2017

By: /s/ Christina Allgeier Christina Allgeier Chief Financial Officer Exhibit No. 99.1

Exhibit Description
September 12, 2017 STRATA Skin Sciences, Inc. investor presentation



### STRATA SKIN SCIENCES

We Believe in Better

#### **Dedicated to Skin Sciences**

Medical Dermatology XTRAC Laser and Systems

for Psoriasis, Eczema, Vitiligo

Aesthetics Nordlys Multiplatform Laser

Stratapen for Microneedling

Large Opportunities, Better Products, Mix of Reimbursed and For Pay Offerings

SIRAL

### STRATA SKIN SCIENCES

### We Believe in Better

2016 Results

Revenues \$31.7M

• GM 60.2%

GAAP Adj EBITDA \$2.9M

No Guidance for 2017

- · 2017 Changes
  - Discontinuation of MelaFind product
  - Distribution Agreement for Nordlys Aesthetic Laser
  - · OEM Relationship for Stratapen
  - Proxy out for Debt Conversion
  - · Realignment of Significant Field Infrastructure



## Medical Dermatology We Believe in Better

- XTRAC Excimer Laser, VTRAC lamp system
  - Psoriasis 6-8M patients US
    - Over 2M treatments
    - Fully reimbursed treatment
    - · Proven Effective
    - Outstanding Side Effect Profile
  - Working on next gen recurring revenue product (2018) with the goal of significantly expanding our addressable market





#### **Psoriasis**



BEFORE TREATMENT




**AFTER TREATMENT** 

### Vitiligo




BEFORE TREATMENT



AFTER TREATMENT





CONFIDENTIAL - DO NOT DISTRIBUTE

SKIN SCIENCE!

### Medical Aesthetics We Believe in Better

- Nordlys
  - Distribution Agreement for US with Ellipse A/S
  - Aesthetic Platform with SWT (next gen IPL), YAG Laser and FRAX
  - Better product for enhanced Patient comfort
  - 6,500 placements WW but only 400 US
  - Significant growth in Aesthetics with both core and non-core physicians. Nordlys is less painful and cuts downtime post procedure for most applications





### nordlys

HYBRID SYSTEM

- Treats Skin Types I-VI
  - 3 Year Warranty
- Fastest Patient Throughput
- Patented Dual-Mode Filtration
  - Low Fluence Required
- Fewer Pulses Per Treatmer

"It's been getting patients into the office for hair reduction, pigments, rosacea...virtually painless..less treatments...great results"

-John M. Taylor, N. Plastic Surge

SVT
SELECTIVE WAVEBAND TECHNOLOGY

LASER DESIGNED FOR COMFORT & EFFICACY

FRAX 1550







### PIGMENT CONCERNS





VL+

Single Treatment Pulses/Tx J/cm<sup>2</sup>

Pigmentation 3 Treatments • 90 Days Treatment Total
Total Pulses Total J/cm<sup>2</sup>
210 1680





VL+

Single Treatment
Pulses/Tx J/cm<sup>2</sup>

Pigmentation 1 Treatment • 120 Days

Treatment Total
Total Pulses Total J/cm²



#### Stratapen

- Approved for delivery of pigment under the skin
- Patented features to prevent contamination
- · Better pull through the skin
- Regionally sold until our OEM Agreement
- Getting strong reviews from KOLs
- Strong Disposable Trail





## STRATA 2017 We Believe in Better

- Assimilate New Products, get Traction
- Improve Profitability of XTRAC Business
- Revitalize B2B and B2C Activities
- Leverage Sales and Support Infrastructure (60 people) with distributed/ OEM products, gain additional access
- Partner with Customers by providing best-in-class products for Practice Revenue with both
  - Reimbursed Medical Procedures, and
  - Aesthetic For Pay Procedures



## STRATA 2018 We Believe in Better

- Renew the XTRAC business with better protocols and enhanced H/W and UI/UX
  - Make the treatments more convenient and more efficacious
  - Graphical interface for patient data
  - Better display
- Develop versions that will be amenable to penetrating socialized medicine markets
- New Products in the Aesthetic space
  - Already under development



### Summary

- Adding two advantaged Aesthetic products will drive incremental revenues at higher profit levels
- Revamping our tools for patient awareness and driving repeat business through Social Media
- Updating and Upgrading the XTRAC franchise to capture significantly more market share
- Having Value Solutions and Educational Support to help Medical Practices grow revenues and attract patients







### NORDLYS

Experience the most versatile vascular and rejuvenation platform on the market.

What once required a room full of devices can now be done with one better skin solution. The Nordlys Hybrid System offers head-to-toe treatment options providing a better patient, provider and practice experience.

CONTACT US

- This 'new class of laser' is customizable and scalable to suit your practice needs
- Offering the latest evolution of light-based technology:
  - SWT Applicators
    - Selective Waveband Technology
    - The precision of a laser with the flexibility of an IPL
- Nd:YAG 1064 Laser
  - Designed for comfort and efficacy
- FRAX 1550 Laser
  - o New and unique non-ablative laser





